Over the last 12 months, AbCellera Biologics insiders reported 8 buys totaling $2.6M and no sales across SEC Form 4 filings.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 24, 2026 | Hayden Michael RD | ▲ Buy | 53,613 | $10.64 | $570K | +4.1% | indirect |
| Aug 18, 2026 | Montalbano John S.D | ▲ Buy | 10,000 | $11.03 | $110K | +4.1% | — |
| Aug 14, 2026 | Booth AndrewChief Financial Officer · O | ▲ Buy | 37,200 | $10.32 | $384K | +8.3% | — |
| Aug 12, 2026 | Hayden Michael RD | ▲ Buy | 46,387 | $10.37 | $481K | +3.6% | indirect |
| Feb 27, 2026 | Thermopylae Holdings Ltd.10% | ▲ Buy | 38,000 | $3.44 | $131K | +0.1% | — |
| Feb 27, 2026 | Booth AndrewChief Financial Officer · O | ▲ Buy | 42,600 | $3.42 | $146K | +27.8% | — |
| Feb 26, 2026 | Thermopylae Holdings Ltd.10% | ▲ Buy | 177,457 | $3.27 | $580K | +0.3% | — |
| Nov 26, 2025 | Montalbano John S.D | ▲ Buy | 50,000 | $3.57 | $178K | +29.2% | — |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? AbCellera Biologics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ABCL feed.